Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBIO vs AYTU: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AYTU Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 6–4 Matrix Metrics)

AYTU Overall Winner 6-Pillar Tally: IBIO 2 – 3 AYTU (1 Tie) Matrix Metrics: IBIO 4 – 6 AYTU

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over iBio, Inc. (IBIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). IBIO carries a Unified Composite Score of 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin).

  • Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. IBIO 46.0/100 HOLD) and 0.65β · 35% Vol risk profile, whereas IBIO leads top-line expansion (+975.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: IBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBIO vs AYTU
IBIO NASDAQ
iBio, Inc. Common Stock
Pharmaceutical Preparations
$0.72
-2.04% 1D
Market Cap $53.7M
TTM Revenue $1.1M
Forward P/E N/M
Beta / 30D Vol 2.07β · 89% Vol
Unified Composite Score
46.0 / 100 HOLD
Tech 45.0 Fund 46.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -20.5%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $0.78 · SMA50: $0.97
AYTU NASDAQ Head-to-Head Winner
AYTU BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$1.81
+1.69% 1D
Market Cap $19.6M
TTM Revenue $58M
Forward P/E 9.2x
Beta / 30D Vol 0.65β · 35% Vol
Unified Composite Score
48.9 / 100 HOLD
Tech 49.0 Fund 53.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.8%), weak momentum, RSI 38
RSI-14: 37.7 · SMA20: $1.89 · SMA50: $2.00

6-Pillar Scorecard Institutional Category Breakdown (IBIO 2 – 3 AYTU)

Columns: Metric · IBIO · AYTU
1. Valuation Multiples AYTU
Forward P/E N/M 9.2x
Trailing P/E N/M 9.2x
PEG Ratio N/M N/M
EV / Revenue 7.8x 0.3x
2. Growth & Scale IBIO
Revenue Growth (YoY) +975.0% +6.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.1M $58M
Market Cap $53.7M $19.6M
3. Profitability & Quality IBIO
Gross Margin 100.0% 64.0%
Operating Margin -3025.6% -14.4%
Net Profit Margin 0.0% -24.8%
Return on Equity (ROE) -51.8% -52.5%
4. Balance Sheet & Cash Flow AYTU
Cash Generation (TTM) -$22M -$1.4M
Cash Flow Margin N/A -2.4%
Net Cash / Leverage $45M Net Cash $4.9M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat AYTU
OpEx & R&D Intensity N/A 78.4% of Rev ($45M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBIO (4) vs AYTU (6)
Institutional Metric IBIO AYTU Criterion Row Edge
Market Capitalization
Scale
$53.7M $19.6M Larger Scale IBIO
Trailing P/E Ratio
Valuation
N/M 9.2x Lower Multiple AYTU
Forward P/E Ratio
Valuation
N/M 9.2x Lower Multiple AYTU
Revenue Growth (YoY)
Growth
+975.0% +6.4% Higher Growth IBIO
Operating Margin (TTM)
Profitability
-3025.6% -14.4% Higher Margin AYTU
Net Profit Margin
Profitability
0.0% -24.8% Higher Margin IBIO
Return on Equity (ROE)
Capital Efficiency
-51.8% -52.5% Higher ROE IBIO
52-Week Range Position
Momentum
1% ($1–$4) 5% ($2–$3) Stronger Trend AYTU
Beta / 30D Volatility
Risk Regime
2.07β · 89% Vol 0.65β · 35% Vol Lower Realized Risk AYTU
Unified Institutional Score
Composite Signal
46.0 / 100 (HOLD) 48.9 / 100 (HOLD) Higher Composite AYTU
Trailing 12M Revenue (USD)
Operating Scale
$1.1M $58M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 64.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 7.8x EV/Rev N/M PEG · 0.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$22M ($45M Net Cash) -$1.4M ($4.9M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IBIO +4.81 pp
IBIO: -6.46% · AYTU: -11.27%
3M Horizon AYTU +27.26 pp
IBIO: -50.57% · AYTU: -23.31%
6M Horizon AYTU +35.71 pp
IBIO: -49.52% · AYTU: -13.81%
1Y Horizon AYTU +25.53 pp
IBIO: -37.67% · AYTU: -12.14%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IBIO Revenue AYTU Revenue IBIO Op. Margin AYTU Op. Margin Margin Leader
FY2019 $0M $10M -782.4% -230.1% AYTU
FY2020 $0M $30M -854.9% -76.5% AYTU
FY2021 $0M $70M -1312.1% -89.7% AYTU
FY2022 $0M $100M -1576.3% -113.7% AYTU
FY2023 N/A $110M N/A -15.9% AYTU
FY2024 $0M $70M -7392.9% -2.4% AYTU
FY2025 $0M $70M -4650.5% -11.8% AYTU
FY2026 $0M $60M -35141.0% -14.4% AYTU

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBIO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AYTU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AYTU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $53.7M market capitalization and -3025.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AYTU Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $19.6M market capitalization and -14.4% operating margin.
OpEx & R&D Reinvestment 78.4% of Rev ($45M)
90D Engineering Disclosures 0 Published

Investor FAQ IBIO vs AYTU Key Questions & Quantitative Answers

As of Nov 16, 2026, AYTU BioPharma, Inc. (AYTU) is the stronger overall head-to-head candidate over iBio, Inc. (IBIO) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Balance Sheet & Cash Flow, R&D & Supply-Chain Moat). IBIO carries a Unified Composite Score of 46.0/100 (HOLD) at $0.72 (N/M Forward P/E, -3025.6% operating margin), whereas AYTU carries 48.9/100 (HOLD) at $1.81 (9.2x Forward P/E, -14.4% operating margin). Growth vs. Quality Trade-Off: AYTU earns the overall head-to-head edge with a stronger Unified Composite Score (48.9/100 HOLD vs. IBIO 46.0/100 HOLD) and 0.65β · 35% Vol risk profile, whereas IBIO leads top-line expansion (+975.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: IBIO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7); meanwhile AYTU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 37.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBIO leads the Growth & Scale pillar: IBIO posts +975.0% YoY revenue growth and +0.0% YoY earnings growth on $1.1M TTM revenue (100.0% gross margin, -3025.6% operating margin), compared with AYTU at +6.4% YoY revenue growth and +0.0% YoY earnings growth on $58M TTM revenue (64.0% gross margin, -14.4% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), IBIO cumulative revenue shifted N/A while AYTU shifted +500.0%. In operating R&D and SG&A reinvestment, IBIO deploys N/A (0 90-day corporate R&D disclosures) versus 78.4% of Rev ($45M) (0 disclosures) for AYTU.

AYTU screens cheaper on headline valuation multiples. IBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.8x EV/Revenue (unreported FCF margin), whereas AYTU trades at 9.2x Forward P/E, 9.2x Trailing P/E, N/M PEG, and 0.3x EV/Revenue (-2.4% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBIO (-51.8% ROE) versus AYTU (-52.5% ROE) capital efficiency.

In options market volatility and institutional positioning, IBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 89% Vol realized risk). By comparison, AYTU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.65β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.